Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries

Summary: Aniracetam, a drug used for dementia and Alzheimer’s, has shown potential in treating various central nervous system disorders based on new animal model studies. Despite promising results in these studies, there is no definitive proof yet that these benefits will translate to human clinical trials, though further research is likely.

Link: PubMed

Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders

Summary: Aniracetam, a nootropic drug, shows potential in enhancing cognition and may benefit elderly patients with mild to moderate Alzheimer’s-related cognitive impairment, performing better than placebo and piracetam in several tests. Preliminary studies suggest it is well tolerated without significant side effects, warranting further research to confirm its efficacy and identify suitable patient profiles.

Link: PubMed

Treatment of insomnia by concomitant therapy with Zopiclone and Aniracetam in patients with cerebral infarction, cerebroatrophy, Alzheimer’s disease and Parkinson’s disease

Summary: The study investigated the combined use of Zopiclone and Aniracetam for treating insomnia in nine elderly patients with various disorders, showing that the therapy effectively increased sleep duration by over 50% in 7 out of 9 cases. The researchers also explored the underlying mechanisms for this effect based on existing literature.

Link: PubMed

Comparative kinetic studies and pH-rate profiling of aniracetam degradation using validated stability-indicating RP-HPLC method

Summary: Researchers developed a reliable HPLC method to study the stability and degradation kinetics of the cognitive enhancer drug aniracetam under various conditions. They found that aniracetam is more stable in neutral conditions compared to acidic or basic environments, and their method can effectively be used in quality control labs to detect and measure aniracetam and its degradation products.

Link: ScienceDirect

Aniracetam and DNQX affect the acquisition of rapid tolerance to ethanol in mice

Summary: This study investigated how different substances affect the development of rapid tolerance to ethanol in mice using a rotarod test. Researchers found that aniracetam, which activates AMPA/kainate receptors, facilitated ethanol tolerance, while DNQX, which blocks AMPA receptors, prevented it, suggesting the involvement of non-NMDA receptors in ethanol tolerance.

Link: ScienceDirect

Sensitive and selective liquid chromatography–tandem mass spectrometry method for the quantification of aniracetam in human plasma

Summary: Researchers developed a precise and sensitive method using LC–MS/MS to measure aniracetam levels in human plasma, achieving a detection limit of 0.2 ng/mL. This method showed reliable results and was successfully used to study aniracetam’s pharmacokinetics in healthy male Chinese volunteers.

Link: ScienceDirect

Postnatal aniracetam treatment improves prenatal ethanol induced attenuation of AMPA receptor-mediated synaptic transmission

Summary: This study found that moderate alcohol exposure during pregnancy impairs brain cell communication related to learning and memory in rat offspring, but treatment with aniracetam after birth can reverse these problems. This suggests that aniracetam might help correct cognitive deficits in conditions like fetal alcohol syndrome.

Link: ScienceDirect

Development and validation of a liquid chromatographic method for the simultaneous determination of aniracetam and its related substances in the bulk drug and a tablet formulation

Summary: Researchers developed a reliable method using high performance liquid chromatography with UV detection to simultaneously identify aniracetam and its related impurities in bulk drug and tablet forms. The method was validated for various parameters including precision, accuracy, and stability, ensuring its efficacy for quality control purposes.

Link: ScienceDirect

Ameliorating effects of preadolescent aniracetam treatment on prenatal ethanol-induced impairment in AMPA receptor activity

Summary: This study found that rats exposed to ethanol before birth showed impaired synaptic transmission in the brain, which was improved by treating with aniracetam, a compound that enhances AMPA receptor function. The treated rats exhibited improved synaptic properties and cognitive potential, suggesting aniracetam could help mitigate alcohol-related cognitive deficits.

Link: ScienceDirect

Determination of aniracetam’s main metabolite, N-anisoyl-GABA, in human plasma by LC–MS/MS and its application to a pharmacokinetic study

Summary: Researchers have developed a quick and accurate method using liquid chromatography–mass spectrometry to measure a key metabolite of the drug aniracetam in human plasma. This method, notable for its efficiency and precision, was successfully used in studying how the body processes aniracetam after a single dose.

Link: ScienceDirect